At a Duke-Margolis and FDA workshop on rare disease statistics, an agency statistician made the trade-off explicit: a ...
Vir's elebsiran-tobevibart combo achieves Phase 3 primary endpoint in hepatitis delta, with 44% reaching undetectable virus ...
Werewolf's WTX-330 shows partial response in early cancer trial, demonstrating manageable tolerability across dose escalation ...
Lindus Health ran a Phase 2a neurology trial for $1M. Impressive, but AI's cost wins are hiding the problem it hasn't solved: ...
Faeth's PIKTOR combination achieved a 33% response rate in heavily pretreated endometrial cancer patients with PI3K pathway ...
Tafolecimab cuts LDL-C over 65% as monotherapy in Phase 3 trial, offering a statin-free option for hypercholesterolemia ...
Pasritamig plus JNJ-9401 produced PSA reductions of at least 50% in 73% of heavily pretreated metastatic prostate cancer ...
UMBRAA masking strategy targets psychedelic trial unblinding bias. With FDA's July 2026 guidance now live, here's what it ...
Icotrokinra meets ACR20 endpoint in Phase 3 psoriatic arthritis trial, with 58% of biologic-naive patients achieving response ...
Checkpoint inhibitor combos are dominating oncology pipelines, but a structural gap between trial design and FDA approval ...
QIAGEN selects Medrio EDC to streamline in vitro diagnostic studies with cost control and internal form configuration ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results